Remote haemodynamic-guided heart failure management in France: Results from the CardioMEMS HF System Post-Market Study (COAST) French cohort
Archives of Cardiovascular Diseases · 2024-11 · 117 (11) · 624-632
DOI: 10.1016/j.acvd.2024.08.003 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Archives of Cardiovascular Diseases, 2024-11. Verfasst von Pascal de Groote und 16 weiteren Autor:innen. Beteiligte Einrichtung: Service de cardiologie, Inserm U1167, institut Pasteur de Lille, CHU de Lille, 59000 Lille, France. Electronic address: pascal.degroote@chu-lille.fr. Hauptthemen laut MEDLINE: Heart Failure, Feasibility Studies, Hemodynamics, Ventricular Function, Left. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Abbott Laboratories, Abbott Vascular Inc.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
BACKGROUND: Previous studies have demonstrated the benefit of a haemodynamic-guided management strategy with the CardioMEMS™ HF System. No data from French patients have been published. AIMS: To analyse the feasibility, safety and clinical benefit of the CardioMEMS™ HF System in 103 French patients included in the CardioMEMS HF System Post-Market Study (COAST). METHODS: Prospective open-label cohort of New York Heart Association class III patients with at least one heart failure hospitalization in the 12 months before enrolment, regardless of left ventricular ejection fraction. The primary safety endpoints assessed the freedom from device/system-related complications and from pressure sensor failure at 2 years after implantation. The primary efficacy endpoint was evaluated comparing the rate of heart failure hospitalization during the year before and the year after implantation. RESULTS: At 2 years, there were no device/system-related complications or pressure sensor failures (P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service de cardiologie, Inserm U1167, institut Pasteur de Lille, CHU de Lille, 59000 Lille, France. Electronic address: pascal.degroote@chu-lille.fr.
- Department of Cardiology, Nord Hospital, AP-HM, Aix-Marseille University, 13015 Marseille, France.
- Department of Cardiology, CHU de Caen, 14033 Caen, France.
- Hôpital Privé du Confluent, 44000 Nantes, France.
- Department of Cardiology, Timone University Hospital, Aix-Marseille University, 13005 Marseille, France.
- CHRU Albert-Michallon, 38700 La Tronche, France.
Förderung
- Abbott Laboratories
- Abbott Vascular Inc
Zitieren
APA
de Groote, P., Thuny, F., Blanchart, K., Gueffet, J. P., Habib, G., Salvat, M., Leclercq, C., Mouquet, F., Roncalli, J., Sebbag, L., Cassagneau, R., Peyrol, M., Sabatier, R., Gazzola, C., Henderson, J., Adamson, P. B., & Roubille, F. (2024). Remote haemodynamic-guided heart failure management in France: Results from the CardioMEMS HF System Post-Market Study (COAST) French cohort. Archives of Cardiovascular Diseases, 117(11), 624-632. https://doi.org/10.1016/j.acvd.2024.08.003
Vancouver
de Groote P, Thuny F, Blanchart K, Gueffet JP, Habib G, Salvat M, et al. Remote haemodynamic-guided heart failure management in France: Results from the CardioMEMS HF System Post-Market Study (COAST) French cohort. Archives of Cardiovascular Diseases. 2024;117(11):624-632. doi:10.1016/j.acvd.2024.08.003
BibTeX
@article{deGroote2024,
author = {de Groote, Pascal and Thuny, Franck and Blanchart, Katrien and Gueffet, Jean-Pierre and Habib, Gilbert and Salvat, Muriel and Leclercq, Christophe and Mouquet, Frederic and Roncalli, Jérôme and Sebbag, Laurent and Cassagneau, Romain and Peyrol, Michael and Sabatier, Remi and Gazzola, Carlo and Henderson, John and Adamson, Philip B and Roubille, François},
title = {Remote haemodynamic-guided heart failure management in France: Results from the CardioMEMS HF System Post-Market Study (COAST) French cohort},
journal = {Archives of Cardiovascular Diseases},
year = {2024},
volume = {117},
number = {11},
pages = {624--632},
doi = {10.1016/j.acvd.2024.08.003}
}
EUVIMED